Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Capecitabine in HER2- Advanced Breast Cancer
NCT02754011Phase 1Completed
- Sponsor
- Unicancer
- Start
- Feb 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Unicancer. Primary endpoints: Maximum Tolerated Dose at 21 days and Recommended Phase 2 Dose at 21 days. Started Feb 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02754011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754011.